These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25348640)

  • 1. Pharmaceutical pricing, cost containment and new treatments for rare diseases in children.
    Stella P; Gold-von Simson G
    Orphanet J Rare Dis; 2014 Oct; 9():152. PubMed ID: 25348640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reference pricing.
    Pentecost MJ
    J Am Coll Radiol; 2013 Dec; 10(12):891. PubMed ID: 24295934
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of the ACA on Health Care Cost Containment.
    Weiner J; Marks C; Pauly M
    LDI Issue Brief; 2017 Feb; 24(4):1-7. PubMed ID: 28378960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Problematic Jumps in Drug Prices and What You Can Do.
    Shaughnessy AF
    Am Fam Physician; 2017 Jul; 96(1):16-18. PubMed ID: 28671371
    [No Abstract]   [Full Text] [Related]  

  • 5. [Medicoeconomic data on rare disease drugs: a move towards more transparency?].
    Schwebig A; Duguet C; Ferry A; Bougé C; Fagon JY; Bismuth C; Ramon J
    Presse Med; 2012 May; 41 Suppl 1():S57-64. PubMed ID: 22487716
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinton versus Trump on health care.
    Jaffe S
    Lancet; 2016 Nov; 388(10057):2223. PubMed ID: 27825495
    [No Abstract]   [Full Text] [Related]  

  • 7. Strategies for managing prescription drug costs.
    Stern L
    Bus Health; 1990 Jun; 8(6):41-2, 44. PubMed ID: 10104793
    [No Abstract]   [Full Text] [Related]  

  • 8. The share of people with high medical costs increased prior to implementation of the Affordable Care Act.
    Cunningham PJ
    Health Aff (Millwood); 2015 Jan; 34(1):117-24. PubMed ID: 25561652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing the cost drivers of medical injectables.
    Johnson KA
    Manag Care Interface; 2003 Apr; 16(4):37-40. PubMed ID: 12747140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost containment: Europe. Germany.
    Burchardi H; Schuster HP; Zielmann S
    New Horiz; 1994 Aug; 2(3):364-74. PubMed ID: 8087598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in the Regulation of High-Cost Treatments: An Overview From Brazil.
    Pereira LC; Sturzenegger DVR; Ortiz J; Ayad NME; Cortopassi WA; Safatle LP; Khuri N
    Value Health Reg Issues; 2019 Dec; 20():191-195. PubMed ID: 31733406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National health spending in 2013: growth slows, remains in step with the overall economy.
    Hartman M; Martin AB; Lassman D; Catlin A;
    Health Aff (Millwood); 2015 Jan; 34(1):150-60. PubMed ID: 25472958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helping to manage the high cost of rare diseases.
    Hesselgrave BL
    Manag Care Q; 2003; 11(1):1-6. PubMed ID: 12790059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. State strategies to address medicaid prescription spending: negotiated pricing vs price transparency.
    Noh S; Janousek CL; Park JH
    Health Econ Policy Law; 2021 Apr; 16(2):201-215. PubMed ID: 32349843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obamacare: what the Affordable Care Act means for patients and physicians.
    Hall MA; Lord R
    BMJ; 2014 Oct; 349():g5376. PubMed ID: 25338761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Affordable Care Act, health care reform, prescription drug formularies and utilization management tools.
    Ung BL; Mullins CD
    Res Social Adm Pharm; 2015; 11(3):459-67. PubMed ID: 25217142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pricing and reimbursement of orphan drugs: the need for more transparency.
    Simoens S
    Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Containing medicines costs in the private sector--the example of a medical benefit scheme.
    Hukins G; Boyce D
    S Afr Med J; 1990 Aug; 78(3):152-4. PubMed ID: 2116045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of approaches for the management of specialty pharmaceuticals in the United States.
    Patel BN; Audet PR
    Pharmacoeconomics; 2014 Nov; 32(11):1105-14. PubMed ID: 25118989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare reform in the United States and China: pharmaceutical market implications.
    Daemmrich A; Mohanty A
    J Pharm Policy Pract; 2014; 7(1):9. PubMed ID: 25097759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.